IL17A and psoriasis: In psoriasis, anti-IL-17 antibodies and the anti-IL-23p19 antibody are highly effective [33, 34], but the results of the phase II trial of MT-1303 were inferior to the effects of these antibodies (EudraCT number 2012-005750-27).